Vitamin D Status Impacts Inflammation and Risk of Infections During Pregnancy

Sponsor

Cornell University (Other)

Overall Status

Completed

CT.gov ID

NCT01815047

Collaborator

University of Rochester (Other)

Enrollment

Location

Arms

76.9

Duration (Months)

1.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The goal of this study is to characterize the function and efficacy of the bioactive nutrient, vitamin D, in relation to infection and inflammatory status across pregnancy. The three specific aims of this study are 1) To address the impact of maternal vitamin D status on inflammation and infections across pregnancy using retrospective data, 2) To address the impact of vitamin D supplementation on maternal vitamin D status, inflammation and infections across pregnancy using prospective data and 3) To assess the impact of maternal vitamin D status during pregnancy on inflammatory mediators at the level of the placenta.

Condition or Disease	Intervention/Treatment	Phase
Inflammation Infection	Dietary Supplement: Vitamin D3 Supplementation	N/A

Detailed Description

Archived serum collected from 158 adolescents at mid-gestation (approximately 26 weeks) and delivery will be analyzed for inflammatory cytokines. The impact of these inflammatory markers will be assessed by comparing the data to measures of vitamin D (25(OH)D, calcitriol and parathyroid hormone) and infections and inflammatory complications abstracted from medical charts. Placental samples were collected from a subset (n=132) of these pregnant teens and these tissues will be analyzed using genome wide microarray of messenger ribonucleic acid (mRNA) and microRNA (miRNA) related to inflammatory processes. A separate group of pregnant adolescents (n=140) will be recruited at entry into prenatal care for a vitamin D supplementation trial. Teens will be randomly assigned to one of two supplements (200 IU D3/d vs. 2000 IU D3/d). Similar to the retrospective analysis, maternal calciotropic hormones and inflammatory cytokines will be assessed at entry into the study, mid-gestation (23-28 weeks) and at delivery. Inflammatory processes and infections reported across pregnancy will be evaluated in relation to vitamin D status and inflammatory markers.

Study Design

Study Type:

Interventional

Actual Enrollment :

85 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double (Participant, Investigator)

Primary Purpose:

Basic Science

Official Title:

Vitamin D Status Impacts Inflammation and Risk of Infections During Pregnancy

Study Start Date :

Dec 1, 2012

Actual Primary Completion Date :

Dec 1, 2015

Actual Study Completion Date :

May 1, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: 200 IU Vitamin D3 A singular daily dose of 200 IU vitamin D3	Dietary Supplement: Vitamin D3 Supplementation
Experimental: 2000 IU Vitamin D3 A singular daily dose of 2000 IU vitamin D3	Dietary Supplement: Vitamin D3 Supplementation

Arm

Intervention/Treatment

Experimental: 200 IU Vitamin D3

A singular daily dose of 200 IU vitamin D3

Dietary Supplement: Vitamin D3 Supplementation

Experimental: 2000 IU Vitamin D3

A singular daily dose of 2000 IU vitamin D3

Dietary Supplement: Vitamin D3 Supplementation

Outcome Measures

Primary Outcome Measures

Change in Vitamin D status, infections and inflammation across pregnancy after Vitamin D supplementation [Entry into study, mid-gestation and delivery]
Maternal calciotropic hormones (25(OH)D, 1,25(OH)2D, 24,25(OH)2D, and PTH) and inflammatory cytokines (CRP, interleukin [IL]-6 and IL-10 and tumor necrosis factor [TNF]-alpha) will be measured at entry into the study and again at 23-28 weeks gestation and delivery after treatment with 200 IU or 2000 IU D3/d. These measures will be compared to inflammatory processes and infections reported in medical records across pregnancy.

Secondary Outcome Measures

Change in maternal vitamin D status and inflammatory markers in serum [Mid-gestation and delivery]
In a retrospective analysis, inflammatory cytokines (CRP, IL- 6 and IL-10 and TNF-alpha) in archived serum collected from a cohort of 158 adolescents that were longitudinally followed across pregnancy both at mid-gestation and at delivery will be related to 25-hydroxyvitamin D (25(OH)D), 1,25- dihydroxyvitamin D (1,25(OH)2D) and parathyroid hormone (PTH) and medically treated infections and inflammatory conditions abstracted from medical records.
Association of maternal vitamin D status (25(OH)D concentration with longitudinal change in 1,25(OH)2D, PTH, 24,25(OH)2D,and the vitamin D metabolite ratio [Mid-gestation and delivery]

Other Outcome Measures

Vitamin D and placental inflammation [Delivery]
Genome-wide microarray studies of mRNA and miRNA in a subset of placental tissue from adolescents with insufficient (<15 ng/mL) and sufficient vitamin D status (>30 ng/mL) will be screened for differential regulation of genes and gene networks involved in inflammatory processes.
Vaginal microbiome profile [Mid to late gestation]
Vitamin D supplementation (200 IU/d D3 and 2000 IU/d D3), dietary intake, 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D (1,25 (OH)2D), parathyroid hormone(PTH), inflammatory cytokines (CRP, IL- 6 and IL-10 and TNF-alpha) and infection (from medical records) will be related to vaginal microbiome profile.